Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02180867 · OUTCOME

Percentage of Patients Distant Failure Free at 5 Years Following Study Entry

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery · Source last updated 2026-06-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
From enrollment to up to 60 months

What was measured

Defined as disease recurrence at sites other than the primary site and diagnosis and nodes regional to that site (metastatic disease, whether or not present at diagnosis), with or without loco-regional failure. The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model. Data were obtained from institutional reported data.

Analysis population: Patients deemed ineligible in the original cohort are excluded. An additional five (5) patients are excluded in this 5-year analysis as they were deemed ineligible post the initial submission and publication.

Groups in this outcome

Dose-Finding Level 1 CR

Dose-Finding Level 1 CR: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2

Dose-Finding Level 1 RT

Dose-Finding Level 1 RT: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2

Dose-Finding Level 2 RT

Dose-Finding Level 2 RT: Adult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2

Regimen A

Regimen A: Chemoradiation plus pazopanib

Regimen B

Regimen B: Chemoradiation alone

Regimen C

Regimen C: Radiation therapy plus pazopanib

Regimen D

Regimen D: Radiation therapy alone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose-Finding Level 1 CR9
Dose-Finding Level 1 RT9
Dose-Finding Level 2 RT10
Regimen A44
Regimen B41
Regimen C5
Regimen D6

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Dose-Finding Level 1 CR77.78Not reported48.44100.00Not reported
Dose-Finding Level 1 RT33.33Not reported0.0071.05Not reported
Dose-Finding Level 2 RT70.00Not reported32.43100.00Not reported
Regimen A59.89Not reported39.1178.67Not reported
Regimen B62.62Not reported39.9985.24Not reported
Regimen C80.00Not reported39.52100.00Not reported
Regimen D66.67Not reported0.00100.00Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        48.44
        upper Limit
        100.00
        value
        77.78
      2. group Id
        OG001
        lower Limit
        0.00
        upper Limit
        71.05
        value
        33.33
      3. group Id
        OG002
        lower Limit
        32.43
        upper Limit
        100.00
        value
        70.00
      4. group Id
        OG003
        lower Limit
        39.11
        upper Limit
        78.67
        value
        59.89
      5. group Id
        OG004
        lower Limit
        39.99
        upper Limit
        85.24
        value
        62.62
      6. group Id
        OG005
        lower Limit
        39.52
        upper Limit
        100.00
        value
        80.00
      7. group Id
        OG006
        lower Limit
        0.00
        upper Limit
        100.00
        value
        66.67
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      9
    3. group Id
      OG002
      value
      10
    4. group Id
      OG003
      value
      44
    5. group Id
      OG004
      value
      41
    6. group Id
      OG005
      value
      5
    7. group Id
      OG006
      value
      6
    units
    Participants
description
Defined as disease recurrence at sites other than the primary site and diagnosis and nodes regional to that site (metastatic disease, whether or not present at diagnosis), with or without loco-regional failure. The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model. Data were obtained from institutional reported data.
dispersion Type
95% Confidence Interval
groups
  1. description
    Dose-Finding Level 1 CR: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2
    id
    OG000
    title
    Dose-Finding Level 1 CR
  2. description
    Dose-Finding Level 1 RT: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2
    id
    OG001
    title
    Dose-Finding Level 1 RT
  3. description
    Dose-Finding Level 2 RT: Adult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2
    id
    OG002
    title
    Dose-Finding Level 2 RT
  4. description
    Regimen A: Chemoradiation plus pazopanib
    id
    OG003
    title
    Regimen A
  5. description
    Regimen B: Chemoradiation alone
    id
    OG004
    title
    Regimen B
  6. description
    Regimen C: Radiation therapy plus pazopanib
    id
    OG005
    title
    Regimen C
  7. description
    Regimen D: Radiation therapy alone
    id
    OG006
    title
    Regimen D
param Type
NUMBER
population Description
Patients deemed ineligible in the original cohort are excluded. An additional five (5) patients are excluded in this 5-year analysis as they were deemed ineligible post the initial submission and publication.
reporting Status
POSTED
time Frame
From enrollment to up to 60 months
title
Percentage of Patients Distant Failure Free at 5 Years Following Study Entry
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice